COVID-19 vaccines significantly cut MIS-C risk in teens

COVID-19 vaccines significantly cut MIS-C risk in teens

COVID-19 vaccines significantly cut MIS-C risk in teens

(HealthDay)—COVID-19 mRNA vaccination is associated with a lower incidence of multisystem inflammatory syndrome in children (MIS-C) in adolescents, according to a research letter published online Dec. 20 in the Journal of the American Medical Association.

Michael Levy, M.D., Ph.D., from Hôpital Universitaire Robert-Debré in Paris, and colleagues reviewed data from all pediatric patients diagnosed with MIS-C between Sept. 1, 2021, and Oct. 31, 2021.

The researchers report that a total of 107 children with MIS-C were hospitalized in France and, among them, 31 percent were adolescents eligible for vaccination. Adolescents with MIS-C had a median age of 13.7 years, 81 percent were male, and 88 percent were admitted to a pediatric intensive care unit. None of the hospitalized teens were fully vaccinated, although 33 were vaccine-eligible. Seven teens had received one dose, with a median time between vaccine injection and MIS-C onset of 25 days (range 17 to 37 days). After the first vaccine dose, the risk for MIS-C was significantly lower than that seen for unvaccinated adolescents (hazard ratio, 0.09).

“The absence of MIS-C cases in fully vaccinated children prevented calculation of a hazard ratio for this group, but suggests that two doses are warranted for efficient protection,” the authors write.

One author disclosed financial ties to Pfizer.

Severe illness, viral coinfection common in children with COVID-19 hospitalization

More information:
Abstract/Full Text

Copyright © 2021 HealthDay. All rights reserved.

COVID-19 vaccines significantly cut MIS-C risk in teens (2022, January 7)
retrieved 9 January 2022

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.